Publication
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerRhabdomyosarcomacivic_curation1.00
- geneMYOD1civic_curation1.00
- geneTP53civic_curation1.00
- variantMYOD1 L122Rcivic_curation1.00
- variantTP53 ALTERATIONcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 34166060
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| MYOD1 L122R1 | ||||||||
| (prognostic) | Rhabdomyosarcoma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID9532This study evaluated 641 cases of rhabdomyosarcoma (RMS), enrolled on Children’s Oncology Group trials (1998-2017) and UK malignant mesenchymal tumor and RMS2005 trials (1995-2016), for mutations in 3… (full text at CIViC) PMID 34166060 · Shern et al., 2021 · Open in CIViC | civic |
| MYOD1 MYOD1 L122R1 | ||||||||
| (prognostic) | Rhabdomyosarcoma | Prognostic | B | Supports Poor Outcome | 4 | rejected | EID9531This study evaluated 641 cases of rhabdomyosarcoma (RMS), enrolled on Children’s Oncology Group trials (1998-2017) and UK malignant mesenchymal tumor and RMS2005 trials (1995-2016), for mutations in 3… (full text at CIViC) PMID 34166060 · Shern et al., 2021 · Open in CIViC | civic |
| TP53 ALTERATION1 | ||||||||
| (prognostic) | Rhabdomyosarcoma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID9594This study evaluated 641 cases of rhabdomyosarcoma (RMS) that were enrolled in the Children’s Oncology Group (COG) trials from 1998 to 2017 and the UK malignant mesenchymal tumor and RMS2005 trails fr… (full text at CIViC) PMID 34166060 · Shern et al., 2021 · Open in CIViC | civic |